The Common Toxicity Criteria (CTC) define adverse events following cancer therapy. It was designed for use in clinical trials of different therapeutic regimens. It can be used to grade metabolic and laboratory complications..
Parameters:
(1) pH (acidosis or alkalosis)
(2) amylase
(3) bicarbonate
(4) creatine phosphokinase (CK)
(5) calcium
(6) cholesterol
(7) glucose
(8) potassium
(9) magnesium
(10) sodium
(11) triglycerides
(12) uric acid
(13) phosphate
(14) lipase
(15) other metabolic or laboratory change
ULN = upper limit of normal
LLN = lower limit of normal
|
Parameter |
Type |
Finding |
Points |
|
pH |
acidosis |
pH < 7.3 and life-threatening physiologic consequences |
4 |
|
|
|
pH < 7.3 |
3 |
|
|
|
pH >= 7.3 and < LLN |
1 |
|
|
normal |
normal |
0 |
|
|
alkalosis |
pH > ULN and < 7.5 |
1 |
|
|
|
pH > 7.5 |
3 |
|
|
|
pH > 7.5 and life-threatening physiologic consequences |
4 |
|
amylase |
hyper |
normal |
0 |
|
|
|
> ULN and <= 1.5 times ULN |
1 |
|
|
|
> 1.5 and <= 2.0 times ULN |
2 |
|
|
|
> 2.0 and <= 5.0 times ULN |
3 |
|
|
|
> 5 times ULN |
4 |
|
bicarbonate |
hypo |
normal |
0 |
|
|
|
>= 16 mEq/L and < LLN |
1 |
|
|
|
11 - 15 mEq/L |
2 |
|
|
|
8 - 10 mEq/L |
3 |
|
|
|
< 8 mEq/L |
4 |
|
CK |
hyper |
normal |
0 |
|
|
|
> ULN to 2.5 times ULN |
1 |
|
|
|
> 2.5 to <= 5.0 times ULN |
2 |
|
|
|
> 5.0 to <= 10.0 times ULN |
3 |
|
|
|
> 10 times ULN |
4 |
|
calcium |
hypercalcemia |
> 13.5 mg/dL |
4 |
|
|
|
12.6 to 13.5 mg/dL |
3 |
|
|
|
11.6 to 12.5 mg/dL |
2 |
|
|
|
> ULN to 11.5 mg/dL |
1 |
|
|
normal |
normal |
0 |
|
|
hypocalcemia |
< LLN to 8.0 mg/dL |
1 |
|
|
|
7.0 - 7.9 mg/dL |
2 |
|
|
|
6.0 - 6.9 mg/dL |
3 |
|
|
|
< 6.0 mg/dL |
4 |
|
cholesterol |
hyper |
normal |
0 |
|
|
|
> ULN to 300 mg/dL |
1 |
|
|
|
